Request Demo
Last update 23 Jan 2025
YK012
Last update 23 Jan 2025
Overview
Basic Info
Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
4
Clinical Trials associated with YK012CTR20242766
评价YK012治疗B细胞急性淋巴细胞白血病的安全性、耐受性、药代动力学特征和初步抗肿瘤疗效的多中心、开放性、Ib/Ⅱ期临床研究
[Translation] A multicenter, open-label, phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary anti-tumor efficacy of YK012 in the treatment of B-cell acute lymphoblastic leukemia
NCT06580301
An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YK012 in Participants with B-cell Acute Lymphoblastic Leukemia
NCT06565689
A Multi-center, Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
100 Clinical Results associated with YK012
Login to view more data
100 Translational Medicine associated with YK012
Login to view more data
100 Patents (Medical) associated with YK012
Login to view more data
100 Deals associated with YK012
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| CD19-positive B-cell acute lymphoblastic leukemia | Phase 2 | CN | 25 Sep 2024 | |
| B-cell lymphoma recurrent | Phase 1 | CN | 09 May 2023 | |
| B-cell lymphoma refractory | Phase 1 | CN | 09 May 2023 | |
| Systemic Lupus Erythematosus | IND Approval | CN | 13 Jan 2025 | |
| Idiopathic Membranous Glomerulonephritis | IND Approval | CN | 31 Dec 2024 | |
| Myasthenia Gravis | Preclinical | CN | 01 Dec 2024 | |
| Scleroderma, Systemic | Preclinical | CN | 01 Dec 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free